Partners Capital Investment Group LLP Increases Position in argenex SE $ARGX

Key Points

• Partners Capital Investment Group LLP increased its holdings in argenex SE by 88.5%, bringing their total shares to 8,124, valued at approximately $4.81 million.
• Institutional investors now own 60.32% of argenex SE stock, with notable purchases including GAMMA Investing LLC, which drastically increased its stake by 53,684.9% during the first quarter.
• Argenex reported a better-than-expected $3.74 EPS for the last quarter, exceeding analyst estimates by $0.90, with total revenue of approximately $866.79 million.

Partners Capital Investment Group LLP increased its holdings in argenex SE (NASDAQ:ARGX - Free Report) by 88.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 8,124 shares of the company's stock after purchasing an additional 3,815 shares during the quarter. Partners Capital Investment Group LLP's holdings in argenex were worth $4,808,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of ARGX. Point72 Asset Management L.P. acquired a new stake in argenex in the 4th quarter valued at $91,013,000. GAMMA Investing LLC lifted its holdings in argenex by 53,684.9% during the first quarter. GAMMA Investing LLC now owns 135,538 shares of the company's stock valued at $802,200,000 after purchasing an additional 135,286 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in argenex by 215.8% during the first quarter. Assenagon Asset Management S.A. now owns 110,390 shares of the company's stock valued at $65,336,000 after purchasing an additional 75,435 shares in the last quarter. Lord Abbett & CO. LLC grew its position in shares of argenex by 33.2% in the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company's stock valued at $162,585,000 after purchasing an additional 68,498 shares during the period. Finally, Lazard Asset Management LLC increased its stake in shares of argenex by 1,086.6% during the fourth quarter. Lazard Asset Management LLC now owns 70,637 shares of the company's stock worth $43,440,000 after purchasing an additional 64,684 shares in the last quarter. 60.32% of the stock is owned by institutional investors and hedge funds.

argenex Price Performance

NASDAQ:ARGX opened at $660.97 on Thursday. The company's 50-day moving average is $592.00 and its two-hundred day moving average is $597.99. argenex SE has a 1-year low of $510.05 and a 1-year high of $696.21. The firm has a market capitalization of $40.45 billion, a price-to-earnings ratio of 33.90, a PEG ratio of 0.76 and a beta of 0.39.

argenex (NASDAQ:ARGX - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $3.74 EPS for the quarter, beating the consensus estimate of $2.84 by $0.90. The firm had revenue of $866.79 million for the quarter, compared to analyst estimates of $776.82 million. argenex had a net margin of 40.98% and a return on equity of 21.06%. As a group, equities analysts anticipate that argenex SE will post 3.13 earnings per share for the current fiscal year.

Analyst Ratings Changes

ARGX has been the topic of a number of research reports. HC Wainwright raised their price target on shares of argenex from $720.00 to $774.00 and gave the company a "buy" rating in a research note on Friday, August 1st. Citigroup reissued a "buy" rating on shares of argenex in a report on Wednesday, May 21st. Guggenheim raised their target price on argenex from $1,060.00 to $1,070.00 and gave the company a "buy" rating in a research report on Friday, August 1st. JMP Securities set a $699.00 price target on argenex in a research note on Wednesday, May 14th. Finally, JPMorgan Chase & Co. boosted their price target on argenex from $775.00 to $830.00 and gave the stock an "overweight" rating in a research report on Monday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating and eighteen have issued a Buy rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and an average price target of $746.81.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.

Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.